{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:31:13Z","timestamp":1792103473887,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2019R1A2C1008619"],"award-info":[{"award-number":["2019R1A2C1008619"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2019H1A2A1076925"],"award-info":[{"award-number":["2019H1A2A1076925"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2018-NR031048"],"award-info":[{"award-number":["RS-2018-NR031048"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2024-00352291"],"award-info":[{"award-number":["RS-2024-00352291"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12272-025-01580-y","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:36:51Z","timestamp":1762868211000},"page":"1345-1361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histone demethylase KDM4C confers temozolomide resistance to glioblastoma cells by epigenetically regulating E2F6"],"prefix":"10.1007","volume":"48","author":[{"given":"Go Woon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Hyun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Yeon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3753-4415","authenticated-orcid":false,"given":"So Hee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"8","key":"1580_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis CD, Jenuwein T (2016) The molecular hallmarks of epigenetic control. Nat Rev Genet 17(8):487\u2013500. https:\/\/doi.org\/10.1038\/nrg.2016.59","journal-title":"Nat Rev Genet"},{"key":"1580_CR2","doi-asserted-by":"publisher","unstructured":"Brennan CW, Verhaak RG, Mckenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O\u2019neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, Network TR (2013) The somatic genomic landscape of glioblastoma. Cell 155(2): 462\u2013477. https:\/\/doi.org\/10.1016\/j.cell.2013.09.034.","DOI":"10.1016\/j.cell.2013.09.034"},{"issue":"5","key":"1580_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","volume":"6","author":"M Butler","year":"2020","unstructured":"Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, Trepel J, Aldape K, Pommier Y, Wu J (2020) MGMT status as a clinical biomarker in glioblastoma. Trends Cancer 6(5):380\u2013391. https:\/\/doi.org\/10.1016\/j.trecan.2020.02.010","journal-title":"Trends Cancer"},{"issue":"5","key":"1580_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1158\/0008-5472.CAN-19-1229","volume":"80","author":"Y Chen","year":"2020","unstructured":"Chen Y, Fang R, Yue C, Chang G, Li P, Guo Q, Wang J, Zhou A, Zhang S, Fuller GN, Shi X, Huang S (2020) Wnt-induced stabilization of KDM4C is required for Wnt\/beta-catenin target gene expression and glioblastoma tumorigenesis. Cancer Res 80(5):1049\u20131063. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1229","journal-title":"Cancer Res"},{"issue":"2","key":"1580_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440\u2013446. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947","journal-title":"Cancer Res"},{"issue":"7","key":"1580_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.neo.2018.05.001","volume":"20","author":"MC De Gooijer","year":"2018","unstructured":"De Gooijer MC, De Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, Van Tellingen O (2018) Improved brain penetration and antitumor efficacy of Temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia 20(7):710\u2013720. https:\/\/doi.org\/10.1016\/j.neo.2018.05.001","journal-title":"Neoplasia"},{"issue":"3","key":"1580_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3892\/ijo.2022.5393","volume":"61","author":"W Diao","year":"2022","unstructured":"Diao W, Zheng J, Li Y, Wang J, Xu S (2022) Targeting histone demethylases as a potential cancer therapy (Review). Int J Oncol 61(3):103. https:\/\/doi.org\/10.3892\/ijo.2022.5393","journal-title":"Int J Oncol"},{"key":"1580_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canlet.2021.07.012","volume":"520","author":"Y Gao","year":"2021","unstructured":"Gao Y, Liu Y, Liu Y, Peng Y, Yuan B, Fu Y, Qi X, Zhu Q, Cao T, Zhang S, Yin L, Li X (2021) UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-mediated chromatin modifications. Cancer Lett 520:172\u2013183. https:\/\/doi.org\/10.1016\/j.canlet.2021.07.012","journal-title":"Cancer Lett"},{"issue":"11","key":"1580_CR9","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41419-018-1176-7","volume":"9","author":"X Ge","year":"2018","unstructured":"Ge X, Pan MH, Wang L, Li W, Jiang C, He J, Abouzid K, Liu LZ, Shi Z, Jiang BH (2018) Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a\/Bad\/Bax axis. Cell Death Dis 9(11):1128. https:\/\/doi.org\/10.1038\/s41419-018-1176-7","journal-title":"Cell Death Dis"},{"issue":"1","key":"1580_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41420-022-01230-y","volume":"8","author":"L Gong","year":"2022","unstructured":"Gong L, Yin Y, Chen C, Wan Q, Xia D, Wang M, Pu Z, Zhang B, Zou J (2022) Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma. Cell Death Discov 8(1):438. https:\/\/doi.org\/10.1038\/s41420-022-01230-y","journal-title":"Cell Death Discov"},{"key":"1580_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111302","volume":"127","author":"C Gong","year":"2024","unstructured":"Gong C, Tu Z, Long X, Liu X, Liu F, Liu J, Zhu X, Li J, Huang K (2024) Predictive role of E2F6 in cancer prognosis and responses of immunotherapy. Int Immunopharmacol 127:111302. https:\/\/doi.org\/10.1016\/j.intimp.2023.111302","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1580_CR12","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.cell.2025.02.023","volume":"188","author":"ZH Gray","year":"2025","unstructured":"Gray ZH, Honer MA, Ghatalia P, Shi Y, Whetstine JR (2025) 20 years of histone lysine demethylases: from discovery to the clinic and beyond. Cell 188(7):1747\u20131783. https:\/\/doi.org\/10.1016\/j.cell.2025.02.023","journal-title":"Cell"},{"issue":"17","key":"1580_CR13","doi-asserted-by":"publisher","first-page":"1900782","DOI":"10.1002\/advs.201900782","volume":"6","author":"K Huang","year":"2019","unstructured":"Huang K, Liu X, Li Y, Wang Q, Zhou J, Wang Y, Dong F, Yang C, Sun Z, Fang C, Liu C, Tan Y, Wu X, Jiang T, Kang C (2019) Genome-wide CRISPR-Cas9 screening identifies NF-kappaB\/E2F6 responsible for EGFRvIII-associated temozolomide resistance in glioblastoma. Adv Sci (Weinh) 6(17):1900782. https:\/\/doi.org\/10.1002\/advs.201900782","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"1580_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1215\/15228517-2008-090","volume":"11","author":"GJ Kitange","year":"2009","unstructured":"Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11(3):281\u2013291. https:\/\/doi.org\/10.1215\/15228517-2008-090","journal-title":"Neuro Oncol"},{"issue":"1","key":"1580_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-021-00674-5","volume":"6","author":"T Lang","year":"2021","unstructured":"Lang T, Xu J, Zhou L, Zhang Z, Ma X, Gu J, Liu J, Li Y, Ding D, Qiu J (2021) Disruption of KDM4C-ALDH1A3 feed-forward loop inhibits stemness, tumorigenesis and chemoresistance of gastric cancer stem cells. Signal Transduct Target Ther 6(1):336. https:\/\/doi.org\/10.1038\/s41392-021-00674-5","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1580_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41419-020-03380-2","volume":"12","author":"DH Lee","year":"2021","unstructured":"Lee DH, Kim GW, Yoo J, Lee SW, Jeon YH, Kim SY, Kang HG, Kim DH, Chun KH, Choi J, Kwon SH (2021) Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc. Cell Death Dis 12(1):89. https:\/\/doi.org\/10.1038\/s41419-020-03380-2","journal-title":"Cell Death Dis"},{"issue":"1","key":"1580_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1215\/15228517-2008-081","volume":"11","author":"L Li","year":"2009","unstructured":"Li L, Dutra A, Pak E, Labrie JE 3rd, Gerstein RM, Pandolfi PP, Recht LD, Ross AH (2009) EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol 11(1):9\u201321. https:\/\/doi.org\/10.1215\/15228517-2008-081","journal-title":"Neuro Oncol"},{"issue":"1","key":"1580_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s40478-025-02046-4","volume":"13","author":"H Li","year":"2025","unstructured":"Li H, Wu Y, Chen Y, Lv J, Qu C, Mei T, Zheng Y, Ye C, Li F, Ge S, Yao A, Jia L (2025) Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights. Acta Neuropathol Commun 13(1):126. https:\/\/doi.org\/10.1186\/s40478-025-02046-4","journal-title":"Acta Neuropathol Commun"},{"issue":"10","key":"1580_CR19","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1158\/1078-0432.CCR-14-0084","volume":"20","author":"F Lin","year":"2014","unstructured":"Lin F, De Gooijer MC, Roig EM, Buil LC, Christner SM, Beumer JH, Wurdinger T, Beijnen JH, Van Tellingen O (2014) ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res 20(10):2703\u20132713. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0084","journal-title":"Clin Cancer Res"},{"key":"1580_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fonc.2018.00249","volume":"8","author":"A Lo Dico","year":"2018","unstructured":"Lo Dico A, Martelli C, Diceglie C, Lucignani G, Ottobrini L (2018) Hypoxia-inducible factor-1alpha activity as a switch for glioblastoma responsiveness to temozolomide. Front Oncol 8:249. https:\/\/doi.org\/10.3389\/fonc.2018.00249","journal-title":"Front Oncol"},{"issue":"12","key":"1580_CR21","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1093\/brain\/awv287","volume":"138","author":"H Luo","year":"2015","unstructured":"Luo H, Chen Z, Wang S, Zhang R, Qiu W, Zhao L, Peng C, Xu R, Chen W, Wang HW, Chen Y, Yang J, Zhang X, Zhang S, Chen D, Wu W, Zhao C, Cheng G, Jiang T, Lu D, You Y, Liu N, Wang H (2015) C-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma. Brain 138(12):3654\u20133672. https:\/\/doi.org\/10.1093\/brain\/awv287","journal-title":"Brain"},{"issue":"8","key":"1580_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/ncponc1155","volume":"5","author":"MM Mrugala","year":"2008","unstructured":"Mrugala MM, Chamberlain MC (2008) Mechanisms of disease: temozolomide and glioblastoma\u2013look to the future. Nat Clin Pract Oncol 5(8):476\u2013486. https:\/\/doi.org\/10.1038\/ncponc1155","journal-title":"Nat Clin Pract Oncol"},{"issue":"11","key":"1580_CR23","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/stem.2703","volume":"35","author":"F Orzan","year":"2017","unstructured":"Orzan F, De Bacco F, Crisafulli G, Pellegatta S, Mussolin B, Siravegna G, D\u2019ambrosio A, Comoglio PM, Finocchiaro G, Boccaccio C (2017) Genetic evolution of glioblastoma stem-like cells from primary to recurrent tumor. Stem Cells 35(11):2218\u20132228. https:\/\/doi.org\/10.1002\/stem.2703","journal-title":"Stem Cells"},{"key":"1580_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172798","author":"J Paluszczak","year":"2025","unstructured":"Paluszczak J, Kleszcz R (2025) The targeted inhibition of histone lysine demethylases as a novel promising anti-cancer therapeutic strategy-an update on recent evidence. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17172798","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1580_CR25","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3390\/ijms25063116","volume":"25","author":"M Raguz","year":"2024","unstructured":"Raguz M, Tarle M, Muller D, Tomasovic-Loncaric C, Chudy H, Marinovic T, Chudy D (2024) ABCG2 expression as a potential survival predictor in human gliomas. Int J Mol Sci 25(6):3116. https:\/\/doi.org\/10.3390\/ijms25063116","journal-title":"Int J Mol Sci"},{"key":"1580_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115187","volume":"165","author":"A Rezaee","year":"2023","unstructured":"Rezaee A, Tehrany PM, Tirabadi FJ, Sanadgol N, Karimi AS, Ajdari A, Eydivandi S, Etemad S, Rajabi R, Rahmanian P, Khorrami R, Nabavi N, Aref AR, Fan X, Zou R, Rashidi M, Zandieh MA, Hushmandi K (2023) Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: function of non-coding RNAs. Biomed Pharmacother 165:115187. https:\/\/doi.org\/10.1016\/j.biopha.2023.115187","journal-title":"Biomed Pharmacother"},{"key":"1580_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.20517\/cdr.2024.157","volume":"8","author":"A Shahani","year":"2025","unstructured":"Shahani A, Slika H, Elbeltagy A, Lee A, Peters C, Dotson T, Raj D, Tyler B (2025) The epigenetic mechanisms involved in the treatment resistance of glioblastoma. Cancer Drug Resist 8:12. https:\/\/doi.org\/10.20517\/cdr.2024.157","journal-title":"Cancer Drug Resist"},{"issue":"24","key":"1580_CR28","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.1158\/1078-0432.CCR-19-0955","volume":"25","author":"Z Sharifi","year":"2019","unstructured":"Sharifi Z, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot MC, Jean-Claude B, Sabri S (2019) Mechanisms and antitumor activity of a binary EGFR\/DNA-targeting strategy overcomes resistance of glioblastoma stem cells to temozolomide. Clin Cancer Res 25(24):7594\u20137608. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0955","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1580_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.20517\/cdr.2020.79","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S (2021) Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist 4(1):17\u201343. https:\/\/doi.org\/10.20517\/cdr.2020.79","journal-title":"Cancer Drug Resist"},{"issue":"5","key":"1580_CR30","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/med.21955","volume":"43","author":"YQ Song","year":"2023","unstructured":"Song YQ, Yang GJ, Ma DL, Wang W, Leung CH (2023) The role and prospect of lysine-specific demethylases in cancer chemoresistance. Med Res Rev 43(5):1438\u20131469. https:\/\/doi.org\/10.1002\/med.21955","journal-title":"Med Res Rev"},{"issue":"1","key":"1580_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, Yang P, Chen C, Ding W, Tillement O, Bai H, Zhang S (2025) Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Ther 10(1):219. https:\/\/doi.org\/10.1038\/s41392-025-02266-z","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"1580_CR32","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1002\/ijc.33375","volume":"148","author":"J Sterling","year":"2021","unstructured":"Sterling J, Menezes SV, Abbassi RH, Munoz L (2021) Histone lysine demethylases and their functions in cancer. Int J Cancer 148(10):2375\u20132388. https:\/\/doi.org\/10.1002\/ijc.33375","journal-title":"Int J Cancer"},{"key":"1580_CR33","doi-asserted-by":"publisher","unstructured":"Stupp R, Brada M, Van Den Bent MJ, Tonn JC, Pentheroudakis G, Group EGW (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 (Suppl 3): iii93\u2013101. https:\/\/doi.org\/10.1093\/annonc\/mdu050.","DOI":"10.1093\/annonc\/mdu050"},{"key":"1580_CR34","unstructured":"Tamimi AF, Juweid M (2017) Epidemiology and Outcome of Glioblastoma. In: De Vleeschouwer, S. (ed) Glioblastoma, Codon Publications, Brisbane (AU)."},{"issue":"1","key":"1580_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Ma T, Yu B (2023) Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther 8(1):69. https:\/\/doi.org\/10.1038\/s41392-023-01341-7","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1580_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41419-025-07617-w","volume":"16","author":"P Wang","year":"2025","unstructured":"Wang P, Liao B, Gong S, Guo H, Zhao L, Liu J, Wu N (2025) Temozolomide promotes glioblastoma stemness expression through senescence-associated reprogramming via HIF1alpha\/HIF2alpha regulation. Cell Death Dis 16(1):317. https:\/\/doi.org\/10.1038\/s41419-025-07617-w","journal-title":"Cell Death Dis"},{"issue":"15","key":"1580_CR37","doi-asserted-by":"publisher","first-page":"8324","DOI":"10.3390\/ijms22158324","volume":"22","author":"Q Wu","year":"2021","unstructured":"Wu Q, Berglund AE, Etame AB (2021) The impact of epigenetic modifications on adaptive resistance evolution in glioblastoma. Int J Mol Sci 22(15):8324. https:\/\/doi.org\/10.3390\/ijms22158324","journal-title":"Int J Mol Sci"},{"key":"1580_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/2040622321997259","volume":"12","author":"L Xue","year":"2021","unstructured":"Xue L, Li C, Ren J, Wang Y (2021) KDM4C contributes to cytarabine resistance in acute myeloid leukemia via regulating the miR-328-3p\/CCND2 axis through MALAT1. Ther Adv Chronic Dis 12:2040622321997259. https:\/\/doi.org\/10.1177\/2040622321997259","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"1580_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12935-022-02659-y","volume":"22","author":"S Yuan","year":"2022","unstructured":"Yuan S, Yan Q, Zhao ZY, Zhang JL, Zhang H, Yin H, Yuan Z (2022) STAT3-mediated upregulation of LINC00520 contributed to temozolomide chemoresistance in glioblastoma by interacting with RNA-binding protein LIN28B. Cancer Cell Int 22(1):248. https:\/\/doi.org\/10.1186\/s12935-022-02659-y","journal-title":"Cancer Cell Int"},{"issue":"11","key":"1580_CR40","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1111\/cns.14277","volume":"29","author":"ZX Zhang","year":"2023","unstructured":"Zhang ZX, Ren P, Cao YY, Wang TT, Huang GH, Li Y, Zhou S, Yang W, Yang L, Liu GL, Xiang Y, Pei YC, Chen QZ, Chen JX, Lv SQ (2023) HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma. CNS Neurosci Ther 29(11):3430\u20133445. https:\/\/doi.org\/10.1111\/cns.14277","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"1580_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40364-025-00788-w","volume":"13","author":"L Zhang","year":"2025","unstructured":"Zhang L, Yang Y, Li Y, Wang C, Bian C, Wang H, Wang F (2025a) Epigenetic regulation of histone modifications in glioblastoma: recent advances and therapeutic insights. Biomark Res 13(1):80. https:\/\/doi.org\/10.1186\/s40364-025-00788-w","journal-title":"Biomark Res"},{"issue":"1","key":"1580_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12935-025-03770-6","volume":"25","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Xiao X, Yang G, Jiang X, Jiao S, Nie Y, Zhang T (2025b) STAT3\/TGFBI signaling promotes the temozolomide resistance of glioblastoma through upregulating glycolysis by inducing cellular senescence. Cancer Cell Int 25(1):127. https:\/\/doi.org\/10.1186\/s12935-025-03770-6","journal-title":"Cancer Cell Int"},{"issue":"5","key":"1580_CR43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.20892\/j.issn.2095-3941.2023.0011","volume":"20","author":"J Zhou","year":"2023","unstructured":"Zhou J, Tong F, Zhao J, Cui X, Wang Y, Wang G, Kang C, Liu X, Wang Q (2023) Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance. Cancer Biol Med 20(5):385\u2013400. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0011","journal-title":"Cancer Biol Med"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-025-01580-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:35:32Z","timestamp":1764952532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-025-01580-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":43,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1007\/s12272-025-01580-y","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author So Hee Kwon is an Associate Editor of this journal Archives of Pharmacal Research, but this position had no influence on the editorial decision or the peer review process of this manuscript. The other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}